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To evaluate colorectal cancer screening with faecal occult blood testing (FOBT) in terms of prevention of advanced cancers, we
conducted a case–control study in the areas where an annual screening programme with immunochemical FOBT has been offered
to all inhabitants aged 40 years or over. Cases were 357 consecutive patients in the study areas clinically diagnosed as having
advanced colorectal cancer or a tumour invading the muscularis propriae or deeper, that is, T2–T4 in TNM classification. Three
controls were selected for each case matched by gender, age, residential area and exposure status to screening within 1 year before
case diagnosis. The odds ratios (ORs) of developing advanced cancer were calculated using conditional logistic regression analyses.
The OR for those screened within 3 years before the diagnosis vs those not screened was 0.54 (95% confidence interval (CI) 0.29–
0.99). The ORs were lower for rectum than for colon (0.32–0.73 and 0.84–1.18 for rectum and colon, respectively). For those
screened within the past 3 years, OR of developing advanced cancer in the rectum was 0.32 ( 95%CI: 0.12–0.84). A screening
programme with immunochemical FOBT can be effective for prevention of advanced colorectal cancer. Risk reduction appears to be
larger for rectal than for colon cancer.
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Colorectal cancer is one of the highest causes of cancer deaths in
many countries (Schottenfeld and Winawer, 1996). Accordingly,
prevention is an issue of global importance. Although colorectal
cancer is considered to be closely related to environmental factors
such as food and life style, effective methods for primary
prevention have yet to be established (Schottenfeld and Winawer,
1996; Rhodes, 2000). Under these circumstances, secondary
prevention by early detection is a practical way to lessen the
burden. Among several modalities that have been proposed for
colorectal cancer screening, the faecal occult blood test (FOBT) or
the Haemoccult test has been demonstrated by three randomised
controlled trials to reduce mortality from colorectal cancer by
15–33% with annual or biennial screening (Mandel et al, 1993,
1999; Hardcastle et al, 1996; Kronborg et al, 1996). It is, therefore,
generally considered that the effectiveness for FOBT has already
been established.
In Japan, screening programmes with various FOBTs by
immunochemical method have been performed. Among the
screening programmes with those FOBTs, efficacy of the screening
by the immunochemical haemagglutination test or the immuno-
chemical FOBT was consistently suggested by several studies,
although they were observational (Hiwatashi et al, 1993; Saito et al,
1995, 2000; Wada et al, 1996; Zappa et al, 1997). Screening with
this type of FOBT is also considered to be effective in terms of
mortality reduction (Young et al, 2002).
The ultimate gains derived from a screening programme are
reductions of serious illness, as well as death, among the people
screened (Morrison, 1992). Reduction of the incidence of advanced
cancer is crucial in terms of quality of life. The immunochemical
FOBT (Saito et al, 1984; Saito, 1996), which is widely used as a
screening test in Japan, has been shown to be superior to the
Haemoccult test in sensitivity, with similar specificity, as reported
both in known colorectal cancer (St John et al, 1993), and in
asymptomatic populations (Iwase 1992; Petrelli et al, 1994; Allison
et al, 1996; Castiglione et al, 1996; Saito and Yoshida, 1996).
Furthermore, sensitivity of the immunochemical FOBT is higher
for adenomas (St John et al, 1993), intramucosal cancer (Iwase
1992; Saito and Yoshida, 1996) and Dukes A cancer (Castiglione
et al, 1996). On the basis of these reports, it is expected that
screening with the immunochemical FOBT provides larger effect
on the incidence reduction of advanced colorectal cancer as
compared to that with the Haemoccult test. This assumption might
be supported by a report that risk of developing an interval cancer
after the immunochemical FOBT is significantly lower than that
after the Haemoccult test (rate ratio¼2.64: Zappa et al, 2001).
The purpose of this study is to evaluate whether screening with
the immunochemical FOBT reduces the incidence of advanced
colorectal cancer, which requires surgery. Therefore, in the present
paper, we conducted a case–control study to evaluate whether
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developing advanced colorectal cancer in the area where annual
screening with the immunochemical FOBT has been performed.
MATERIAL AND METHODS
Study district and screening programme
Colorectal cancer screening has been conducted using a one-day
immunochemical FOBT test (Imudia-Hem Sp: Fujirebio, Tokyo,
Japan) since 1986 in Aomori Prefecture, Japan. Details of the study
district and the screening programme were described in a previous
paper (Saito et al, 1995). The district consists of two small cities, 13
towns and 11 villages. The entire population of the screening areas
is 276819 in 1992. Screening was annually offered to all men and
women, who held national health insurance, aged 40 years or over
(101136 persons in 1992) through the Aomori Screening Centre
for Cancer and an average of 16000 persons participated in the
screening each year before 1992 (Saito et al, 1995). Accordingly,
the participation rate was approximately 16%. Nearly 60% of the
participants were female subjects. The study area had not had
colorectal cancer screening prior to 1986, and a complete listing of
residents had been conducted just before the programme was
started. The immunochemical FOBT test was performed according
to the original method (Saito et al, 1984; Saito, 1996) at the
laboratory in the Centre and records of all screening examinations
were maintained. A positivity rate for the FOBT was 2.4% (Saito
et al, 1995). Screenees who tested positive for FOBTs were
recommended to undergo diagnostic investigation by sigmoido-
scopy with double-contrast barium enema or by total colonoscopy
at hospitals in or near the study area. Sigmoidoscopy in
combination with barium enema was more prevalent than
colonoscopy as a diagnostic examination in this programme, that
is, 70% or more before 1992. There were 66 cases of colorectal
cancer found in the screening programme during 1989–92.
Screenees, who were found to have colorectal cancers or
adenomas, were treated by surgical or endoscopic resection. The
Centre retrieved detailed information on diagnosis and treatment
from the hospitals at which diagnostic investigation and treatment
were performed.
Definition and selection of cases and controls
Cases were defined as the consecutive patients clinically diagnosed
as having advanced colorectal cancer that invaded to the
muscularis propriae or deeper, which required surgery, that is,
T2–T4 in TNM Clinical Classification or A–C in the original
Dukes classification (Sobin and Wittekind, 1997). Among Dukes A
cancers, those cancers limited to submucosal layer were not
included in advanced cancer cases in this study. Diagnoses of cases
were performed in the study areas from 1 April 1989 to 31
December 1992. For inclusion, case subjects were 40 years or older
at the time of diagnosis and had been living in the same area since
1986 when the screening programme was started. Patients with a
previous history of colorectal cancer were excluded. Potential case
subjects were obtained from the files of the cancer registries that
cover the whole prefecture. Diagnoses of colorectal cancers were
scrutinised by reviewing medical records for colonoscopic and/or
radiographical findings, anatomic location of the cancer, histolo-
gical diagnosis and depth of cancer invasion.
There were 543 potential case subjects clinically diagnosed
during the period. Confirmation of diagnosis, site and stage of the
cancer was made in 423 subjects by reviewing medical records. A
total of 12 were excluded because they were less than 40 years old
at the time of diagnosis. We further excluded 54 cases of early
cancer whose cancer did not invade muscularis propria. More than
half of these 54 cancers were those confined to the mucosa, but we
could not determine in some cases with or without cancer
extension through muscularis mucosae into the submucosa. In
total, there were 357 cases of clinically diagnosed advanced
colorectal cancers that met the above criteria. All the cases were
identified in the list of residents of the study area. These cases
included 62 fatalities documented in a previous case–control study
(Saito et al, 1995). To minimise the influence of selection bias, they
were included in the case subjects. Among the total of 357 cases,
there were six who had screening tests within 1 year before their
diagnoses. These six had negative FOBT. Further, among 66
screen-detected cancer subjects, there were 33 with advanced
colorectal cancer that also met the above criteria, thus making
them subjects for additional analysis.
For each case, we randomly selected three controls from the list
of residents in 1986 in the study area, where the corresponding
case lived, matched to cases by year of birth (73 years), gender
and residential area within the town or village. According to a
matching criterion for a case–control study that evaluates
screening efficacy in terms of risk of invasive disease (Sasco et al,
1986), controls were matched to cases also by exposure status just
before case diagnoses. For the 351 cases who did not have
screening tests within 1 year before their diagnoses, controls were
required not to have screening tests during the same period. There
were 1047 controls eligible for the above criteria. For the other six
cases, who had screening tests within 1 year before their diagnoses,
and each of 33 screen-detected cases, controls were selected from
among those who participated in the screening programme in the
same year as the case diagnosis. Each control subject had to be
alive when the case subject was diagnosed. Control subjects, with a
history of colorectal cancer before the screening programme was
started in 1986 or 1987, were excluded. Of 1164 controls selected
for 390 cases, 1071 had the same birth year as those of the
corresponding cases. We did not encounter any control subjects
who developed colorectal cancer during the period from 1986 until
the time of case diagnosis.
Comparison of screening history and analyses
Screening histories were investigated by reviewing the records of
the screenees by staff of the Centre who were blind to whether the
subjects were cases or controls. Screening histories of cases and
controls were reviewed within the same calendar period of 5 years
before case diagnosis. Conditional logistic regression analyses were
performed in the same manner as previously reported using PROC
PHREG with the SAS computer programme (Saito et al, 1995). The
odds ratios (ORs) of developing advanced colorectal cancer were
calculated primarily using the above 357 case–control sets. As
screening exposure within 1 year was matched between cases and
controls, it was not used for case–control comparison. Odds ratios
were calculated for those having at least one screening test within
2, 3, 4 and 5 years before case diagnosis vs those having no
screening test in the corresponding periods. To investigate the
optimal screening interval, ORs were also calculated for those
having their most recent screening history in each of the 2–5 years
before the date of diagnosis vs those not screened in that year
segment. With 390 case–control sets including those of 33 screen-
detected cancers and their controls, ORs were also calculated in the
same manner as in the above 357 sets for those having been
screened within 2–5 years before case diagnoses. Statistical
significance was evaluated at a 5% level, and 95% confidence
intervals (CI) were presented for estimated OR.
RESULTS
The age, stage and site distributions of the 357 clinically diagnosed
case subjects are shown in Table 1. Clinical stages were shown
based on the classification of the Japanese Society for Cancer of the
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rectal cancers. The ratio of colon to rectal cancers was higher for
those aged 70 years or over than that for those of younger ages
although not statistically significant. The proportion of stage IV
cancers was higher with colon (35.0%) than with rectal lesions
(19.2%) with a statistical significance (Po0.05 by w
2 test, Table 1)
and was similar among the age groups. The stage distributions of
screen-detected case subjects are also shown in Table 1.
Odds ratios of developing advanced colorectal cancer were
calculated for individuals having screening histories within 2–5
years before case diagnosis, as compared with those not screened,
using 357 case–control sets. Risk of developing advanced color-
ectal cancer was reduced by 28–46% among individuals having at
least one screening within 2–4 years before case diagnosis, with
statistical significance for those screened during the past 3 years
(Table 2). The ORs calculated for the 357 case–control sets by
number of years since the most recent screening were 0.60 (95%
CI: 0.29–1.23) after 2 years and 0.58 (95% CI: 0.22–1.52) after 3
years following the most recent screening, but no reduction in risk
was observed after more than 3 years. When ORs were calculated
including 33 screen-detected cancers and their controls, the values
within 2 and 3 years were closer to unity than those from 357
case–control sets (Table 3). We performed the following analyses
using 357 case–control sets.
Odds ratios of developing advanced colorectal cancer were also
calculated according to the subgroups of gender, age, stage and
anatomic location of the cancer (Tables 4 and 5). Similar ORs were
obtained for males and females. Odds ratios were higher for those
aged 70 years or over than those aged 69 years or younger
(Table 4). There was no significant difference between ORs for
overall cancers and stages I–IIIb (Tables 2 and 5). Regarding
anatomic location, the ORs of developing advanced cancer for
those having at least one screening history within 2–5 years were
higher for the colon than for the rectum with statistical
significance for the OR of developing rectal cancer for those
having screening tests during the past 3 and 4 years (Table 5).
We further calculated ORs for rectal cancers and colon cancers
using stages I–IIIb cancers, because the rates of stage IV cancers
were significantly different between the colon and rectum (Table 1).
Odds ratios for those screened within 2–5 years before case
diagnoses were higher for colon (0.76–1.39) than for rectum
(0.31–0.74) also after excluding stage IV cancers, albeit without
statistical significance.
DISCUSSION
The present study was intended to evaluate the screening with the
immunochemical FOBT in terms of prevention of advanced
cancers in the colorectum that require surgery. Several case–
control studies have shown screening to provide strong protection
against development of advanced cervical cancer (Clark and
Anderson, 1979; Dunn and Schweitzer, 1981; Macgregor et al, 1985;
Van der Graaf et al, 1988) and although there have been no
randomised controlled trials, the efficacy of cervical cancer
screening has therefore been considered to be established. The
present case–control study indicates that screening with immu-
nochemical FOBT reduces the risk of developing advanced
colorectal cancer. Subjects who had undergone at least one
screening test during the previous 4 years had a reduced risk of
bearing advanced colorectal cancer by 28–46% as compared to
those who were unscreened (Table 2).
In this study, main analyses were performed using 357 clinically
diagnosed cancers. This is because, screen-detected and symptom-
detected cases should be kept separate in the analysis to avoid
mixing prevalence and incidence ORs (Sasco et al, 1986). For
Table 1 Clinical characteristics of case subjects with clinically diagnosed
and screen-detected advanced colorectal cancer
Advanced cancer was defined as cancer invaded to the muscularis propriae or
deeper.
aClinical stages were based on the classification proposed by ‘Japanese
Society for Cancer of the Colon and Rectum’ (1995). The stages are mainly defined
by depth of the primary tumour; Stage 0: within the mucosa; Stage I : invading the
submucosa or muscularis propriae; Stage II : beyond the muscularis propriae, but not
directly invading into the other organs; Stages III and IV: directly invading into the
other organs. Regardless of tumour depth, however, metastasis to the first group, the
second or third group and the fourth group lymph nodes indicates Stage IIIa, Stage IIIb
and Stage IV, respectively. Stage IV can be diagnosed by existence of peritoneal or
distant metastasis.
bCase subjects with tumour invasion limiting to the submucosa
were excluded from the present study.
cPo0.05 (by w
2 test).
Table 2 Odds ratios (ORs) of developing advanced colorectal cancer in individuals screened within 2,3,4
and 5 years before case diagnoses
Number of subjects available
a Number of subjects screened (%)
b
Years before
diagnosis Cases Controls Cases Controls ORs (95% CI)
Within
2 years 357 1065 10 (2.8%)
c 47 (4.4%)
c 0.60 (0.29–1.23)
3 349 1040 14 (4.0) 72 (6.9) 0.54 (0.30–0.99)
4 311 931 23 (7.4) 92 (9.9) 0.72 (0.44–1.17)
5 218 649 24 (11.0) 74 (11.4) 0.96 (0.57–1.59)
aThe number of subjects who had the chance to participate in screening during each period.
bSubjects with screening
histories/number of subjects (%). Odds ratios were calculated for previous history within 2, 3, 4 and 5 years before case was
diagnosed as having advanced cancer compared with no screening history in those intervals, using conditional logistic
regression analysis.
cNumber of subjects who had screening histories within 1 year before case diagnosis was not included,
as screening exposure status within 1 year of case diagnosis was matched between cases and controls. ORs within 1 year
are equal to that of within 2 year.
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rather than incidence, rates of disease among various screening
histories (Sasco et al, 1986). The purpose of this study is to
estimate the incidence rate of advanced colorectal cancer among
those with screening histories as compared to those without having
them. Accordingly, ORs were calculated using clinically diagnosed
cases and their controls and then including screen-detected case–
control sets. When analyses were performed including 33 screen-
detected cases and their controls, ORs within 2 and 3 years became
closer to 1.0 than the original ORs (Tables 2 and 3). This might be
because, the time at which diagnosis is made shifts forward
depending on the distribution of lead times. Controls were
matched to cases by exposure status just before case diagnoses.
This matching was done because a chance of appearing in the
study as cases, which must be equal between a case and controls of
a matched set, is different depending on with or without screening
exposure just before case diagnoses (Sasco et al, 1986). This is
straightforward in asymptomatic screen-detected cases and their
controls, and it might be the same for symptom-detected cases and
controls. In fact, ORs were much lower when screening histories
were compared between 357 cases and their controls matched only
by sex, age and residential area, that is, 0.18(95% CI: 0.08–0.42),
0.35(0.18–0.70), 0.35(0.20–0.62), 0.48(0.30–0.77) and 0.58(0.36–
0.94) for those screened within 1, 2, 3, 4 and 5 years before case
diagnoses, respectively. Odds ratios shown in Tables 2 and 3 might
be overestimated due to overmatching.
Concerning the degree of efficacy, 60% reduction in risk of
death from colorectal cancer was found in the previous study of
screening using immunochemical FOBT alone (Saito et al, 1995).
Hiwatashi et al (1993) reported 74% reduction of risk for those
Table 3 Odds ratios (ORs) of developing advanced colorectal cancer for those screened within 2, 3, 4 and
5 years before case diagnoses when analysed after inclusion of 33 screen-detected cancers and their controls
Number of subjects available
a Number of subjects screened(%)
b
Years before
diagnosis Cases Controls Cases Controls ORs (95%CI)
Within
2 years 390 1164 26 (6.7%) 94 (8.1%) 0.76 (0.45–1.28)
3 382 1139 34 (8.9) 129 (11.3) 0.69 (0.43–1.10)
4 343 1027 42 (12.2) 155 (15.1) 0.72 (0.47–1.11)
5 243 724 42 (17.3) 127 (17.5) 0.98 (0.62–1.55)
aThe number of subjects who had the chance to participate in screening during each period.
bSubjects with screening
histories/number of subjects (%). Odds ratios were calculated for previous history within 2, 3, 4 and 5 years before case was
diagnosed as having advanced cancer compared with no screening history in those intervals, using conditional logistic
regression analysis.
Table 4 Odds ratios (ORs) of developing advanced colorectal cancer for those screened within 2, 3, 4 and
5 year before diagnosis, in the subgroups according to gender and age
ORs
a (95%CI)
Years before diagnosis
Gender (male/female)
(n¼193/164)
Age (40–69 years/X70 years)
(n¼197/160)
Within
2 years 0.63 (0.23–1.72)/0.58 (0.21–1.59) 0.53 (0.22–1.25)/0.82 (0.23–2.93)
3 0.66 (0.29–1.47)/0.44 (0.18–1.08) 0.47 (0.22–1.00)/0.71 (0.26–1.90)
4 0.78 (0.38–1.59)/0.66 (0.34–1.31) 0.62 (0.33–1.16)/0.92 (0.41–2.06)
5 0.99 (0.47–2.10)/0.93 (0.47–1.86) 0.72 (0.36–1.46)/1.36 (0.64–2.88)
aOdds ratios calculated for previous history within 2, 3, 4 and 5 years before diagnosis, compared with no screening history
in those intervals, using conditional logistic regression analyses. Separate model is used to calculate OR in each line.
Table 5 Odds ratios (ORs) of developing advanced colorectal cancer for those screened within 2, 3, 4 and
5 year before diagnosis, in the subgroups according to clinical stage and anatomical location.
ORs
a (95%CI)
Years before Diagnosis
Stage (I–IIIb/IV)
(n¼260/97)
Location (rectum/colon)
(n¼177/180)
Within
2 years 0.52 (0.22–1.22)/0.90 (0.24–3.36) 0.40 (0.13–1.20)/0.88(0.34–2.26)
3 0.55 (0.28–1.08)/0.53 (0.15–1.87) 0.32 (0.12–0.84)/0.84(0.39–1.81)
4 0.61 (0.34–1.10)/1.10(0.43–2.80) 0.43 (0.19–0.97)/1.06(0.57–2.00)
5 1.01 (0.56–1.81)/0.81(0.28–2.34) 0.73 (0.32–1.68)/1.18(0.61–2.27)
aOdds ratios calculated for previous history within 2, 3, 4 and 5 years before diagnosis, compared with no screening history
in those intervals, using conditional logistic regression analyses. Separate model is used to calculate OR in each line.
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present study to investigate the efficacy of early detection
suggested 46% reduction in risk of developing advanced cancer.
It seems to be reasonable that the magnitude of reduction in risk of
advanced cancer is smaller than that for risk of death from cancer,
because mortality reduction reflects the sum of prevention of
invasive cancers and stage shift of advanced cancers.
A reduction in incidence of colorectal cancer after screening has
recently been demonstrated by a randomised controlled trial,
although the reduced incidence might be attributable to many
colonoscopies performed rather than FOBT screening (Mandel
et al, 2000). Whichever the contributor is, the incidence reduction
would have been achieved through removal of adenomas in the
above trial. In this study, incidence reduction of advanced cancer
was strongly suggested. The reason for reduction in risk of
advanced cancer by screening would be a stage shift of advanced
cancers to early cancers or cancers confined within the submucosal
layer. There were 33 early cancer cases, which were not included in
the cases in this case–control study, among 66 screen-detected
cases during 1989–92. Although the proportion of early cancers
among clinically diagnosed cases could not be determined due to
inability to confirm stages in many subjects, it might be
approximately 13%, that is, 54 early cancers among 423 cases
reviewed, being much lower than that for screen-detected cases.
Another possible reason is presumably the effect of endoscopic
polypectomy of adenomas from which colorectal cancers are
believed to arise (O’Brien et al, 1990; Mandel et al, 2000). Screenees
having colorectal polyps sized 5mm or more were primarily
treated by endoscopic polypectomy in the present study areas.
Therefore, it can be estimated that polypectomy would have been
performed much more frequently than in the unscreened
group. Although there are no comprehensive data available
about polypectomy in screenees, polyps larger than 1cm in
diameter were found in approximately 0.2% of the screenees
through the same screening programme in a neighbouring
area with similar characteristics to the study area (Saito and
Yoshida, 1996). Therefore, it is most likely that reduced risk of
advanced cancer after screening is partially due to the effect of
polypectomy.
In the subgroup analysis according to ages, ORs were higher for
those of 70 years old or over than for those of younger ages
(Table 4). A higher proportion of colon cancer to rectal cancer
among those aged 70 years or older than those of younger ages
might be a reason for this result (see Tables 1, 5 and below). It is
possible that efficacy of preventing advanced colorectal cancer
might be smaller for individuals aged 70 years or over as compared
to that for younger ages. However, this needs to be investigated by
additional studies. In the subgroup analysis by anatomic location,
the ORs of developing advanced cancer for those screened within
2–5 years were higher for the colon (0.84–1.18) than for the
rectum (0.32–0.73) (Table 5). This result was similar to that of a
previous study, which suggested that the OR of developing fatal
cancer with screening within 3 years before case diagnosis was
higher for the colon (0.56) than for the rectum (0.39) (Saito et al,
1995). Although significantly higher proportion of stage IV cancers
was included in subjects with colon cancer than in those with rectal
cancer (Table 1), calculated ORs for colon cancer after excluding
these were still higher than those for rectal. One plausible
explanation is that sensitivity of diagnostic examination is higher
for distal than proximal cancers because the recommended
modality has been flexible sigmoidoscopy in combination with
barium enema. Obviously, barium enema examination is less
sensitive in detecting early lesions than endoscopy. Thus, distal
lesions are more likely to be detected than proximal lesions. It
would be possible that the efficacy of screening differ between
rectal and colon cancers. Several studies have reported that
haemoglobin loses its immunoreactivity during transit through the
colon (Young and St John, 1992; Saito, 1996). Thus, it is possible
that sensitivity of immunochemical FOBT may be higher for rectal
than colon early lesions despite the finding that sensitivity does
not differ between proximal and distal cancers (St John et al, 1992,
1993). Another explanation is that the natural history of cancer
may vary between the rectum and the colon. Genetic alterations
may be different between cancers in the proximal colon and those
in distal sites (Kern et al, 1989), so that a growth differential could
arise. Further studies are clearly needed to explain the difference in
ORs between rectal and colon cancers.
Some potential confounding factors should be considered with
observational studies such as the present case–control investiga-
tion (Cole and Morrison, 1980). Diagnoses of cases, which were
here verified by reviewing the medical records, should be accurate.
Since the screening histories for cases and controls were based on
the same data source, recall bias could be eliminated. In addition,
confounding by effects of previous screening could be excluded
because our case and control subjects had not been screened
before starting the screening programme with immunochemical
FOBT in 1986. Further, the screening histories of each case and the
corresponding controls were evaluated for the same time period
and in exactly the same way. For that reason, differences in the
time frame for collection of cases and controls did not bias
exposure opportunity.
The main defect of case–control studies in the evaluation of the
efficacy of screening is self-selection bias (Cole and Morrison,
1980). It is generally considered that risk of the disease is different
between individuals who are willing to be screened and those who
are not. Accordingly, the efficacy of the screening might be
overestimated. However, in this study, ORs increased with the
extension of duration after the last screening and values were 1.0
or higher for those having their most recent screening test 4–5
years before diagnosis (Table 3), suggesting that self-selection bias
was unlikely to be a major factor. Although the results should be
interpreted with caution, the present study suggests that screening
using immunochemical FOBT provides protection against devel-
opment of advanced stage colorectal cancer.
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